■钠葡萄糖协同转运蛋白2抑制剂由于其心脏保护作用而被推荐用于治疗心力衰竭,尽管主要用作抗糖尿病药物。然而,两种抗糖尿病药物的比较概况,钠葡萄糖协同转运蛋白2抑制剂与二肽基肽酶4抑制剂仍不清楚.
■本研究旨在比较钠葡萄糖协同转运蛋白2抑制剂与二肽基肽酶4抑制剂药物的安全性和有效性。
■在PubMed中进行了全面搜索,Scopus,WebofScience,谷歌学者,和ClinicalTrials.gov从开始到2023年2月23日使用适当的医学主题词。结果使用风险比的随机效应模型进行汇总,置信区间为95%。P值<0.05被认为是统计学上显著的。
■经过系统筛选后纳入了12项研究,钠葡萄糖协同转运蛋白2抑制剂的样本量为745,688,二肽基肽酶4抑制剂的样本量为769,386。各组的平均年龄分别为61.1(8.52)和61.28(9.25)岁,分别。将所包含的物品与钠葡萄糖协同转运蛋白2抑制剂和二肽基肽酶4抑制剂合并后,全因死亡的主要结局显示风险比为0.64(0.57,0.70),I2:65.54%,p<0.001,主要不良心血管事件的风险比为0.76(0.65,0.86),I2:87.83%,p<0.001。次要结局包括心肌梗死,风险比为0.84(0.78,0.90),I2:47.64%,p<0.001,卒中风险比为0.81(0.75,0.87),I2:36.78%,p<0.001,住院风险比为0.62(0.53,0.70),I2:83.32%,p<0.001。
■我们的研究结果表明,与二肽基肽酶4抑制剂相比,开始使用钠葡萄糖协同转运蛋白2抑制剂治疗可提供心血管疾病保护,可在2型糖尿病患者中考虑.
UNASSIGNED: Sodium glucose cotransporter 2 inhibitors are recommended for the treatment of heart failure due to their cardioprotective effects, despite primarily being used as antidiabetic medications. However, the comparative profile of two antidiabetic drugs, sodium glucose cotransporter 2 inhibitors with dipeptidyl peptidase 4 inhibitor remains unclear.
UNASSIGNED: This study aims to compare the safety and efficacy profiles of sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitor drugs.
UNASSIGNED: A comprehensive search was conducted in PubMed, Scopus, Web of Science, Google Scholar, and ClinicalTrials.gov using appropriate Medical Subject Headings terms from inception until February 23, 2023. The outcomes were pooled using a random-effects model for hazard ratio with a 95% confidence interval. A p-value of <0.05 was considered statistically significant.
UNASSIGNED: Twelve studies were included after systematic screening, with a sample size of 745,688 for sodium glucose cotransporter 2 inhibitors and 769,386 for dipeptidyl peptidase 4 inhibitor. The mean age in each group was 61.1 (8.52) and 61.28 (9.25) years, respectively. Upon pooling the included articles with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitor, the primary outcome of all-cause death demonstrated an hazard ratio of 0.64 (0.57, 0.70), I 2: 65.54%, p < 0.001, and major adverse cardiovascular events yielded an hazard ratio of 0.76 (0.65, 0.86), I 2: 87.83%, p < 0.001. The secondary outcomes included myocardial infarction with an hazard ratio of 0.84 (0.78, 0.90), I 2: 47.64%, p < 0.001, stroke with an hazard ratio of 0.81 (0.75, 0.87), I 2: 36.78%, p < 0.001, and hospitalization with an hazard ratio of 0.62 (0.53, 0.70), I 2: 83.32%, p < 0.001.
UNASSIGNED: Our findings suggest that compared to dipeptidyl peptidase 4 inhibitor, initiating treatment with sodium glucose cotransporter 2 inhibitors provides cardiovascular disease protection and may be considered in patients with type 2 diabetes.